Pear Therapeutics (PEAR) has announced that it is to utilize digital therapeutics to treat opioid use disorder (OUD).
The effort will apply “enhanced engagement and gamification mechanisms to reSET and reSET-O, PEAR’s current products for the treatment of substance use disorder (SUD) and OUD.”
PEAR has been the recipient of a Small Business Innovation Research (SBIR) Fast-Track award funded by the National Institute on Drug Abuse (NIDA).
It is using this award to fund its research.
reSET and reSET-O are prescription digital therapeutics comprised of a patient-facing smartphone application and a clinician-facing web interface.
The products have been validated in 5 randomized clinical studies involving more than 1500 patients with SUD and OUD.
These studies have demonstrated that reSET and reSET-O effectively deliver behavioural therapy for addiction conditions and improve patient outcomes including abstinence and programme retention in a variety of clinical settings and treatment intervals ranging from 12 weeks to 12 months.
The pivotal clinical study examining reSET demonstrated a dose-response relationship: a direct correlation between therapeutic module completion and abstinence was observed.
PEAR is exploring methods such as immersive environments, enhanced storytelling, and gamification to support improved module completion, and hence to further improve treatment outcomes.
“We are thrilled to receive this award from NIDA. The project provides us the opportunity to further optimize our products to treat opioid use disorder, creating even more engaging and efficacious treatment options for patients,” said Corey McCann, MD PhD, President and CEO of PEAR.
“I am extremely proud of the partnership that we have developed with PEAR Therapeutics, a leader in the industry,” said Amanda Wilson, MD, President and CEO of the CleanSlate Research and Education Foundation.
PEAR will collaborate with CleanSlate Research and Education Foundation and Columbia University Medical Center Department of Psychiatry’s Division on Substance Use Disorders on the project.
The group will design, implement, and validate next-generation digital therapeutics.
OUD is a chronic, relapsing disease, impacting more than 2.5 million US individuals over the age of 12.
OUD has reached epidemic proportions in the US, with a record 33,091 lethal opioid overdoses in 2015.